Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

argenx NV ADR

ARGX
Current price
457.74 USD +3.96 USD (+0.87%)
Last closed 454.26 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 26 982 416 384 USD
Yield for 12 month +16.40 %
Week
Month
Year
ARGX
21.11.2021 - 28.11.2021

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Address: Willemstraat 5, Breda, Netherlands, 4811 AH

Analytics

WallStreet Target Price

561.05 USD

P/E ratio

Dividend Yield

Current Year

+448 763 444 USD

Last Year

+543 303 499 USD

Current Quarter

+360 313 302 USD

Last Quarter

+295 591 314 USD

Current Year

+416 608 397 USD

Last Year

+543 303 499 USD

Current Quarter

+320 982 340 USD

Last Quarter

+269 343 723 USD

Key Figures ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -227 082 256 USD
Operating Margin TTM -23.5 %
PE Ratio
Return On Assets TTM -10.29 %
PEG Ratio
Return On Equity TTM -13.62 %
Wall Street Target Price 561.05 USD
Revenue TTM 1 028 612 992 USD
Book Value 51.08 USD
Revenue Per Share TTM 0.73 USD
Dividend Share
Quarterly Revenue Growth YOY 132 %
Dividend Yield
Gross Profit TTM -251 786 000 USD
Earnings Share -4.1 USD
Diluted Eps TTM -4.1 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -22.8 %

Dividend Analytics ARGX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARGX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 24.316
Price Sales TTM 26.2318
Enterprise Value EBITDA -84.8793
Price Book MRQ 9.0109

Financials ARGX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ARGX

For 52 weeks

333.07 USD 550.76 USD
50 Day MA 486.93 USD
Shares Short Prior Month 798 338
200 Day MA 437.32 USD
Short Ratio 3.68
Shares Short 835 292
Short Percent 1.93 %